Glenmede Trust CO Na Nektar Therapeutics Transaction History

Glenmede Trust CO Na

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $22,346 - $26,965	-1,417 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $862 - $1,289	-52 Reduced 3.54%	1,417 $23,000
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $19,641 - $27,307	-1,165 Reduced 44.23%	1,469 $34,000
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $67 - $145	-4 Reduced 0.15%	2,634 $47,000
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $126 - $185	4 Added 0.15%	2,638 $88,000
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $80,152 - $149,216	2,634 New	2,634 $86,000
Q3 2018 Nov 15, 2018	SELL	$46.46 - $68.49 $23,090 - $34,039	-497 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$46.25 - $104.45 $2,358 - $5,326	51 Added 11.43%	497 $24,000
Q4 2017 Feb 15, 2018	BUY	$23.02 - $60.5 $10,266 - $26,983	446	446 $26,000

16.1M

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $11.8B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.